Protara Therapeutics, Inc. (TARA) stock
Close on Nov 13, 2026Market cap $149.51MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $149.51M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.06
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$78.45M
- EPS, diluted
- -$1.40
- Free cash flow
- -$56.46M
- Book value per share
- $2.24
- Diluted shares
- 63M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $2.44
- Open
- $2.49
- Day's range
- $2.37 – $2.58
- Volume
- 728,220
- Average volume (20 days)
- 905,125
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.45
- 52-week range
- $2.09 – $7.82
- RSI (14 days)
- 48.7
- Volatility (1 year)
- 72.9%
- Relative volume
- 0.86×
- WACC
- 12.4%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | TARA | S&P 500 | Difference | TARA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.4% | -3.0% | −0.4 pts | ||
| 3 months | -35.8% | -2.8% | −33.0 pts | ||
| Year to date | -52.5% | +11.5% | −64.0 pts | ||
| 1 year | -52.0% | +13.5% | −65.5 pts | ||
| 3 years | +120.0% | +77.7% | +42.3 pts | +30.1% | +21.1% |
| 5 years | -65.5% | +72.6% | −138.1 pts | -19.2% | +11.5% |
| 10 years | -99.3% | +308.2% | −407.5 pts | -39.0% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Protara Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
About Protara Therapeutics
Biological Products, (No Diagnostic Substances)
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its pipeline includes TARA-002, an investigational cell therapy being developed for non-muscle invasive bladder cancer and lymphatic malformations. The company is also developing intravenous choline chloride, a phospholipid substrate replacement therapy intended for adolescent and adult patients dependent on parenteral support when oral or enteral nutrition is not possible, insufficient, or contraindicated. Its intended customer base comprises patients with these oncologic and rare disease conditions who have limited treatment options.
Company profile, executives and historyProtara Therapeutics stock: common questions
What is Protara Therapeutics's stock price?
TARA closed at $2.53 on Nov 13, 2026, up 3.69% on the day. Over the past 52 weeks it traded between $2.09 and $7.82.
What is Protara Therapeutics's market cap?
Protara Therapeutics was worth $149.51M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is TARA's P/E ratio?
Protara Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.40), so it has no meaningful P/E ratio.
Does Protara Therapeutics pay a dividend?
No. Protara Therapeutics has not paid a cash dividend over the last twelve months.
When does Protara Therapeutics report earnings next?
Protara Therapeutics is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TARA stock performed over the past year?
Including dividends, TARA returned -52.0% over the past year, against +13.5% for the S&P 500.
How many TARA shares are sold short?
3M shares were sold short at the latest FINRA report, 5.64% of the float, or 2.9 days of average trading volume.
Who are Protara Therapeutics's competitors?
Companies most similar to Protara Therapeutics by business, industry and size include CRBU, CRIS, ENGN, CERO, INAB.
See a number that looks wrong?